A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of ...
New research suggests that Medicare could save up to 74 percent of the money lost from discarded Alzheimer's drug Leqembi or ...
The number of U.S. children who suffer seizures after swallowing prescription medications or illicit drugs has doubled in ...
Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.
Lecanemab (Leqembi; Eisai/Biogen) received traditional approval from the FDA in July 2023, following an accelerated approval ...
A much-anticipated drug that holds the promise of delaying symptoms of Alzheimer’s disease will not be available in Australia ...
The first drug Leqembi, which is marketed by Biogen BIIB and Japan-partnered Eisai, was approved for use last year. The Biogen-Eisai drug was also approved for use by the FDA last year.
Leqembi (lecanemab), developed in partnership with Eisai, represents a significant opportunity for Biogen in the treatment of early Alzheimer's disease. The drug has shown promise in clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback